Home > News > Veristat strengthens its long standing relationship with aegerion pharmaceuticals

1 min read

Veristat Strengthens Its Long-Standing Relationship with Aegerion Pharmaceuticals

Veristat, a full service Clinical Research Organization (CRO), announced today the signing of a Preferred Provider Agreement (PPA) with Aegerion Pharmaceuticals Inc. (“Aegerion”), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases.  Veristat has assisted Aegerion with US Food and Drug Administration, EU Market Authorization Application, and Japan Food and Drug Administration submission projects over the past 5 years.

Veristat will offer Aegerion clinical trial support including statistical consulting, biostatistical analysis, clinical data management, clinical monitoring, SAS programming, clinical protocol and study report writing, project management and the preparation of regulatory submission documents.

“Veristat has been a strong and dedicated collaborative partner and an extension of our project teams,” said Pamela Foulds, MD, Vice President of Clinical Development at Aegerion Pharmaceuticals.

“Veristat is thrilled to progress to this next phase in our working relationship with Aegerion,” stated Barbara Balser, VMD, Chief Scientific Officer at Veristat. “We feel like a true partner to Aegerion and are eager to continue to deliver quality expertise and services for their marketing applications.”

1 min read

SCOPE: Powering the Future of Clinical Research

Nov 20, 2025  Veristat Events

Meet Veristat at SCOPE: Powering the Future of Clinical Research February 2-5, 2026

🔬 Advancing Clinical Research with...

1 min read

ASH Annual Meeting and Exposition

Oct 22, 2025  Veristat Events

Meet Veristat at ASH Meeting and Exposition December 6-9, 2025

Veristat is excited to attend the ASH Annual Meeting and...